Five Prime Therapeutics to Present at the Jefferies 2017 Global Healthcare Conference
05 juin 2017 17h37 HE
|
Five Prime Therapeutics, Inc.
SOUTH SAN FRANCISCO, Calif., June 05, 2017 (GLOBE NEWSWIRE) -- Five Prime Therapeutics, Inc. (Nasdaq:FPRX), a clinical-stage biotechnology company focused on discovering and developing innovative...
Five Prime Therapeutics Presents Initial Clinical Trial Data from Phase 1/2 trial of Cabiralizumab in Pigmented Villonodular Synovitis (PVNS) at 2017 ASCO Annual Meeting
04 juin 2017 09h05 HE
|
Five Prime Therapeutics, Inc.
SOUTH SAN FRANCISCO, Calif., June 04, 2017 (GLOBE NEWSWIRE) -- Five Prime Therapeutics, Inc. (Nasdaq:FPRX) announced that a poster featuring initial clinical data from the ongoing Phase 1/2 clinical...
Five Prime Therapeutics Presents Updated Data From Phase 1 Trial of Single-Agent FPA144 at 2017 ASCO Annual Meeting
03 juin 2017 09h05 HE
|
Five Prime Therapeutics, Inc.
SOUTH SAN FRANCISCO, Calif., June 03, 2017 (GLOBE NEWSWIRE) -- Five Prime Therapeutics, Inc. (Nasdaq:FPRX) announced that a poster featuring updated data from the ongoing Phase 1 trial of FPA144 was...
Five Prime Welcomes Garry Nicholson to Board of Directors
15 mai 2017 16h05 HE
|
Five Prime Therapeutics, Inc.
SOUTH SAN FRANCISCO, Calif., May 15, 2017 (GLOBE NEWSWIRE) -- Five Prime Therapeutics, Inc. (Nasdaq:FPRX), a clinical-stage biotechnology company focused on discovering and developing innovative...
Five Prime Announces First Quarter 2017 Results and Provides Business Update
04 mai 2017 16h05 HE
|
Five Prime Therapeutics, Inc.
SOUTH SAN FRANCISCO, Calif., May 04, 2017 (GLOBE NEWSWIRE) -- Five Prime Therapeutics, Inc. (Nasdaq:FPRX), a clinical-stage biotechnology company focused on discovering and developing innovative...
Five Prime to Present Clinical Data at 2017 ASCO Annual Meeting
20 avr. 2017 16h10 HE
|
Five Prime Therapeutics, Inc.
SOUTH SAN FRANCISCO, Calif., April 20, 2017 (GLOBE NEWSWIRE) -- Five Prime Therapeutics, Inc. (Nasdaq:FPRX), a clinical-stage biotechnology company focused on discovering and developing innovative...
Five Prime Therapeutics to Announce First Quarter 2017 Financial Results and Host Conference Call on May 4
20 avr. 2017 16h05 HE
|
Five Prime Therapeutics, Inc.
SOUTH SAN FRANCISCO, Calif., April 20, 2017 (GLOBE NEWSWIRE) -- Five Prime Therapeutics, Inc. (NASDAQ:FPRX), a clinical-stage biotechnology company focused on discovering and developing innovative...
Five Prime Therapeutics Announces Completion of Enrollment for the Phase 2 Part of the Ongoing Trial of Cabiralizumab for the Treatment of Pigmented Villonodular Synovitis (PVNS)
10 avr. 2017 16h05 HE
|
Five Prime Therapeutics, Inc.
SOUTH SAN FRANCISCO, Calif., April 10, 2017 (GLOBE NEWSWIRE) -- Five Prime Therapeutics, Inc. (Nasdaq:FPRX) today announced that it has completed enrollment in the initially planned 30-patient...
Five Prime Presents Data on Unique Immuno-Oncology Discovery Research at the 2017 AACR Annual Meeting
03 avr. 2017 13h00 HE
|
Five Prime Therapeutics, Inc.
SOUTH SAN FRANCISCO, Calif., April 03, 2017 (GLOBE NEWSWIRE) -- Five Prime Therapeutics, Inc. (Nasdaq:FPRX), a clinical-stage biotechnology company focused on discovering and developing innovative...
Five Prime Presents Preclinical Research Data on CSF-1R and PD-1 Blockade at the 2017 AACR Annual Meeting
03 avr. 2017 08h00 HE
|
Five Prime Therapeutics, Inc.
SOUTH SAN FRANCISCO, Calif., April 03, 2017 (GLOBE NEWSWIRE) -- Five Prime Therapeutics, Inc. (Nasdaq:FPRX), a clinical-stage biotechnology company focused on discovering and developing innovative...